Effects of the Reactive Metabolite Methylglyoxal on Cellular Signalling, Insulin Action and Metabolism - What We Know in Mammals and What We Can Learn From Yeast.


Journal

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
ISSN: 1439-3646
Titre abrégé: Exp Clin Endocrinol Diabetes
Pays: Germany
ID NLM: 9505926

Informations de publication

Date de publication:
Apr 2019
Historique:
pubmed: 9 2 2018
medline: 16 8 2019
entrez: 9 2 2018
Statut: ppublish

Résumé

Levels of reactive metabolites such as reactive carbonyl and oxygen species are increased in patients with diabetes mellitus. The most important reactive dicarbonyl species, methylglyoxal (MG), formed as by-product during glucose metabolism, is more and more recognized as a trigger for the development and progression of diabetic complications. Although it is clear that MG provokes toxic effects, it is currently not well understood what cellular changes MG induces on a molecular level that may lead to pathophysiological conditions found in long-term diabetic complications. Here we review the current knowledge about the molecular effects that MG can induce in a cell. Within the mammalian system, we will focus mostly on the metabolic effects MG exerts when applied systemically to rodents or when applied

Identifiants

pubmed: 29421830
doi: 10.1055/s-0043-122382
doi:

Substances chimiques

Pyruvaldehyde 722KLD7415

Types de publication

Journal Article Review

Langues

eng

Pagination

203-214

Informations de copyright

© Georg Thieme Verlag KG Stuttgart · New York.

Déclaration de conflit d'intérêts

No conflict of interest has been declared by the authors.

Auteurs

Johanna Zemva (J)

Department of Medicine I and Clinical Chemistry, Heidelberg University Hospital, Heidelberg, Germany.

Daniel Pfaff (D)

Department of Medicine I and Clinical Chemistry, Heidelberg University Hospital, Heidelberg, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.

Jan B Groener (JB)

Department of Medicine I and Clinical Chemistry, Heidelberg University Hospital, Heidelberg, Germany.
German Center for Diabetes Research (DZD), München-Neuherberg, Germany.

Thomas Fleming (T)

Department of Medicine I and Clinical Chemistry, Heidelberg University Hospital, Heidelberg, Germany.
German Center for Diabetes Research (DZD), München-Neuherberg, Germany.

Stephan Herzig (S)

Joint Heidelberg-IDC Translational Diabetes Program, Dept. Inner Medicine I, Heidelberg University Hospital, Germany.
Institute for Diabetes and Cancer IDC, Helmholtz Center Munich, Germany.

Aurelio Teleman (A)

German Cancer Research Center (DKFZ), Heidelberg, Germany.

Peter P Nawroth (PP)

Department of Medicine I and Clinical Chemistry, Heidelberg University Hospital, Heidelberg, Germany.
Joint Heidelberg-IDC Translational Diabetes Program, Dept. Inner Medicine I, Heidelberg University Hospital, Germany.
German Center for Diabetes Research (DZD), München-Neuherberg, Germany.

Jens Tyedmers (J)

Department of Medicine I and Clinical Chemistry, Heidelberg University Hospital, Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH